Patients may neglect their skin health when the weather gets cold, but they remain at risk of damaging their skin and developing cancer in the winter, too. What winter-specific risk factors can clinicians discuss with patients?
Results from both studies showed treatment with Qwo was associated with greater reductions in cellulite severity compared with placebo as measured by CR-PCSS and PR-PCSS scales at day 71.
Janssen announced positive top-line results from two phase 3 trials of Tremfya (guselkumab) in patients with moderate to severe psoriatic arthritis.
According to the results of a retrospective cohort study, male patients who utilize proton pump inhibitors (PPIs) appear to be at increased risk of developing gynecomastia.
